Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6375961 | 0.81 | PTGER4 (0.35) | PTGER4PTGER2DHFRF2RL3 | |
| SCHEMBL6374424 | 0.80 | PTGER4 (0.37) | PTGER4PTGER2DHFR | |
| SCHEMBL27491065 | 0.80 | PTGER4 (0.37) | PTGER4PTGER2DHFR | |
| SCHEMBL6381398 | 0.78 | PTGER4 (0.36) | PTGER4PTGER2DHFR | |
| SCHEMBL6377342 | 0.76 | PTGER4 (0.36) | PTGER4PTGER2 | |
| SCHEMBL6624255 | 0.73 | DHFR (0.55) | DHFRF2RL3KDM4CNPC1RAB9A | |
| SCHEMBL21236930 | 0.72 | KDM4C (0.45) | KDM4CNPC1RAB9A | |
| SCHEMBL7655260 | 0.72 | SLC16A3 (0.33) | PTGER4PTGER2 | |
| SCHEMBL6377017 | 0.72 | SLC16A3 (0.33) | PTGER4PTGER2 | |
| SCHEMBL9123646 | 0.71 | DHFR (0.35) | PTGER4DHFRKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097922-B1 | 5-THIA-OMEGA-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-6586468-B1 | Prostaglandin derivatives having preferential binding to prostaglandin E2 receptors used for prophylaxis of autoimmune and graft versus host diseases, respiratory system, liver and sleep disorders; side effect reduction | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6462081-B1 | SUCH AS A 9-OXO-11,15-DIHYDROXY-16-(3-METHOXYMETHYLPHENYL)-17,18,19,20-TETRANOR-5 -THIAPROST-13-ENOIC ACID; PROSTAGLANDIN E2 RECEPTOR BINDERS; AMYOTROPHIC LATERAL SCLEROSIS, LUPUS, MULTIPLE SCLEROSIS, SJOEGREN'S SYNDROME, RHEUMARTHROSIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1114816-A1 | $g(v)-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-07-11 | — | — | EP | disclosed |
| EP-1097922-A1 | 5-THIA-OMEGA-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-6043275-A | BIND PROSTAGLANDIN E2 RECEPTOR; PREVENTION AND/OR TREATMENT OF IMMUNOLOGICAL DISEASES, ASTHMA, ABNORMAL BONE FORMATION, NEURONAL CELL DEATH, LIVER DAMAGE, NEPHRITIS, HYPERTENSION, MYOCARDIAC ISCHEMIA, SLEEPING DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0985663-A1 | A 3.7-dithiaprostanoic acid derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |